Evaluation of the oncolytic activity of Newcastle disease virus (rLS1) in human prostate and renal carcinoma cell lines
DOI:
https://doi.org/10.15381/anales.v86i1.29785Keywords:
Neoplasms, Newcastle Disease Virus, Oncolytic Virotherapy, Apoptosis, Carcinoma Renal Cell, Prostatic NeoplasmsAbstract
Introduction. Oncolytic virotherapy has emerged as a novel method for treating cancer. The newcastle disease virus (ndv) exhibits oncolytic potential and selectively replicates in tumor cells. Human prostate and renal cancer are the leading causes of death worldwide. Objective. To evaluate the oncolytic activity of the rLS1 viral construct on prostate carcinoma (DU-145) and renal cancer (786-O) cell lines, as well as its selective replication in both tumor lines and the non-tumoral madin-darby canine kidney (MDCK) cell line. Methods. The oncolytic effectiveness was determined by reducing cell viability and apoptosis using the (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2h-tetrazolium) MTS colorimetric assay and by labeling with annexin v/anxa5-pe/sytox blue dead cell, respectively. The viral replicative selectivity in cells was evaluated by crystal violet staining. Results. The MTS assay determined that rls1 significantly reduced viability (p < 0,001) in both tumor cell lines without causing a significant reduction in the viability of MDCK cells compared to uninfected cells. A significant increase (p < 0,001) in the percentage of apoptotic cells was observed in 786-O and DU-145 cells infected with rLS1 compared to uninfected cells. Conclusion. The results indicate that rLS1 demonstrated selective oncolytic potential in human prostate and renal cancer cells, suggesting its potential as an antitumoral agent.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Gloria Guerrero-Fonseca, Brigith Carbajal-Lévano, Aldo Rojas-Neyra, Astrid Poma Acevedo, Freddy Ygnacio, Katherine Calderón, Manolo Fernández-Sánchez, Manolo Fernández-Díaz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Those authors who have publications with this magazine accept the following terms:
- Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
- Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
- Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).
